/Compounds With Anti-tumor Activity Against Cancer Cells Bearing Tyrosine Kinase Inhibitor Resistant Egfr Mutations
Abstract
The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a second-generation quinazolinamine derivative tyrosine kinase inhibitor.
Full Text
What is claimed is:
The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a second-generation quinazolinamine derivative tyrosine kinase inhibitor.
Timeline
Filed
04/28/2026Published
08/20/2026Granted
Not AvailableIPC Codes(8)
A61K 31/506:not condensed and containing further heterocyclic rings
A61K 31/4706:4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/496:Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin